Formulations for pulmonary delivery of dopamine agonists
US6193954A · kind A · utility
14Cited by
9References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 1997 |
| Grant date | Feb 27, 2001 |
| Priority date | — |
| Expiry date | Mar 21, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/473
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods and formulations for administering a dopamine agonist to the airways of a patient. The preferred dopamine agonist is selected from (5aR-trans)-4,5,6,7,11b-hexahydro-2-propylbenzo[f]thieno[2,3-c]quinoline- 9,10) -diol, diacetate (ester) hydrochloride. The delivery method relates to certain aerosol formulations and liquid formulations which are administered into the airways to provide effective delivery of the dopamine agonists to the receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.